Literature DB >> 11072196

Technological and biological evaluation of tablets containing different strains of lactobacilli for vaginal administration.

L Maggi1, P Mastromarino, S Macchia, P Brigidi, F Pirovano, D Matteuzzi, U Conte.   

Abstract

Ten strains of lactobacilli were evaluated for the administration of viable microorganisms to restore the normal indigenous flora in the treatment of urogenital tract infections (UTI) in women. As the strains considered are facultative anaerobes, optimization of the production process was particularly critical to preserve bacterial viability. The microorganisms were formulated in single- and double-layer vaginal tablets. The two layers were characterized by different release properties: one is an effervescent composition that ensures a rapid and complete distribution of the active ingredient over the whole vaginal surface; while the second is a sustained release composition capable of releasing the lactobacilli over a longer period of time. Three different retarding polymers were tested, and all the formulations and tablets were evaluated in terms of technological processability, bacterial viability and stability, and cell adhesion properties of the microorganisms. From the results obtained, three out of ten strains appear particularly suitable for their application in the treatment of UTI. A larger batch of tablets made with a mixture of the three strains was then evaluated, confirming the feasibility of their industrial production and a good bacterial viability in the final dosage form.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072196     DOI: 10.1016/s0939-6411(00)00121-1

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  9 in total

1.  Sustained delivery of commensal bacteria from pod-intravaginal rings.

Authors:  Manjula Gunawardana; Madeline Mullen; Jennifer Yoo; Paul Webster; John A Moss; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

Review 2.  A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections.

Authors:  Valence M K Ndesendo; Viness Pillay; Yahya E Choonara; Eckhart Buchmann; David N Bayever; Leith C R Meyer
Journal:  AAPS PharmSciTech       Date:  2008-04-02       Impact factor: 3.246

3.  Robust vaginal colonization of macaques with a novel vaginally disintegrating tablet containing a live biotherapeutic product to prevent HIV infection in women.

Authors:  Laurel A Lagenaur; Iwona Swedek; Peter P Lee; Thomas P Parks
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

Review 4.  Biological control of vaginosis to improve reproductive health.

Authors:  P Mastromarino; R Hemalatha; A Barbonetti; B Cinque; M G Cifone; F Tammaro; F Francavilla
Journal:  Indian J Med Res       Date:  2014-11       Impact factor: 2.375

5.  Biomedical applications of fermenticin HV6b isolated from Lactobacillus fermentum HV6b MTCC10770.

Authors:  Baljinder Kaur; Praveen P Balgir; Bharti Mittu; Balvir Kumar; Neena Garg
Journal:  Biomed Res Int       Date:  2013-07-29       Impact factor: 3.411

6.  Effects of processing and storage on Pediococcus pentosaceus SB83 in vaginal formulations: lyophilized powder and tablets.

Authors:  Sandra Borges; Paulo Costa; Joana Silva; Paula Teixeira
Journal:  Biomed Res Int       Date:  2013-06-17       Impact factor: 3.411

7.  Lactobacillus crispatus L1: high cell density cultivation and exopolysaccharide structure characterization to highlight potentially beneficial effects against vaginal pathogens.

Authors:  Giovanna Donnarumma; Antonio Molinaro; Donatella Cimini; Cristina De Castro; Vivien Valli; Vincenza De Gregorio; Mario De Rosa; Chiara Schiraldi
Journal:  BMC Microbiol       Date:  2014-05-30       Impact factor: 3.605

Review 8.  Role of Lactobacilli and Lactoferrin in the Mucosal Cervicovaginal Defense.

Authors:  Piera Valenti; Luigi Rosa; Daniela Capobianco; Maria Stefania Lepanto; Elisa Schiavi; Antimo Cutone; Rosalba Paesano; Paola Mastromarino
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

9.  Comparative phase I randomized open-label pilot clinical trial of Gynophilus® (Lcr regenerans®) immediate release capsules versus slow release muco-adhesive tablets.

Authors:  Caroline Dausset; Stéphane Patrier; Pawel Gajer; Claudia Thoral; Yann Lenglet; Jean-Michel Cardot; Philippe Judlin; Jacques Ravel; Adrien Nivoliez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-07-21       Impact factor: 3.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.